Korean vendor Medison is known primarily for its work in ultrasound,so its debut of a new whole-body MRI scanner at the Chicago meetingshould cause a few heads to turn. Medison will display Magnum,an investigational 1-tesla scanner making its U.S.
Korean vendor Medison is known primarily for its work in ultrasound,so its debut of a new whole-body MRI scanner at the Chicago meetingshould cause a few heads to turn. Medison will display Magnum,an investigational 1-tesla scanner making its U.S. conferencedebut. The work-in-progress system was developed over the pastyear as a collaboration between Medison engineers in Korea andstaff employed by Medison subsidiary Atlanta MR in Atlanta.
The company installed the second Magnum system last month inKorea and is planning to apply for regulatory clearance in theU.S., according to Prem Anand, Atlanta MR president. The companyis considering possible distribution of Magnum in Latin Americathrough its ultrasound equipment sales force. Atlanta MR is alsodeveloping a 3-tesla whole body scanner for research spectroscopy,Anand said.
Anand joined Atlanta MR in January, shortly after Medison establishedits U.S. MR operation. He is a veteran of Atlanta-based imagingservices firm Health Images, where he was executive vice presidentin charge of engineering, manufacturing, and product development.
In Medison's more traditional ultrasound business, the companywill display Combison 530, the 3-D ultrasound scanner it acquiredwith its purchase of Austrian firm Kretztechnik in April (SCAN5/22/96). Combison 530 is awaiting 510(k) clearance, which Medisonhopes will be forthcoming by the end of this year, according toMark Hayward, president of Medison's U.S. subsidiary in Pleasanton,CA.
Medison will also debut SonoAce 7700, the company's first color-flowscanner. The system is being sold in international markets buthas just entered the FDA's review process, Hayward said.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men
April 3rd 2025After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.